Stem cell hair transplant: what the evidence can tell you

What does a treatment described as cellular contain?

Stem cells can renew themselves and develop into specialised cells, which makes them an area of interest for medical research. Hair research includes cells obtained from follicles or fatty tissue, as well as substances produced by those cells. Gasteratos and colleagues distinguish treatments containing cells from preparations that contain no living cells in their review of the clinical literature (Gasteratos et al., 2024).

A cell extract, a culture medium containing secreted substances and extracellular vesicles are different preparations. Exosomes belong to the small vesicles involved in communication between cells; describing them as whole stem cells creates confusion. A review published in 2026 brings together several families of preparations and highlights the variation in how they are produced and delivered (Behrangi et al., 2026).

PRP is another preparation, made from blood and enriched with platelets. Our explanation of PRP hair treatment helps separate these terms before you compare proposals. If a provider combines them in one description, ask for the exact product name and composition, then check which preparation the studies they cite actually investigated.

How does this differ from a surgical hair transplant?

In conventional transplantation, the surgeon moves follicular units from a donor region to an area requiring restoration. Harvesting can involve individual units with FUE or a strip of donor scalp with FUT, leaving different scar patterns. The NHS describes these as operations that redistribute existing hair, with their own recovery requirements and possible complications (NHS, 2023).

An injection into the scalp, by itself, does not specify a number of relocated follicles or the implantation of a new hairline. Some commercial procedures also use stem cell terminology for partial follicle harvesting, so you need an explanation of the operation and evidence relevant to that method. Our comparison of DHI and FUE helps you distinguish harvesting from placement when discussing a surgical transplant.

A proposal to multiply the donor supply requires particularly clear evidence about what was measured, where, after how long and in how many people. An increase in density alone cannot establish a renewable supply of grafts. Assessment of the hair transplant donor area therefore remains part of planning surgery, even when an additional treatment is suggested alongside it.

What have studies in people actually shown?

Clinical trials have been conducted, and some report improvements in measured hair parameters. The 2024 review includes 12 randomised trials, but their differences led the authors to review them without pooling the results in a meta-analysis. Tissue sources, preparations and follow-up periods vary, so their findings cannot be converted into one success rate for every treatment carrying a stem cell label (Gasteratos et al., 2024).

One example makes that distinction easier to understand: Tak and colleagues allocated 38 people to either a constituent extract from cells derived from fatty tissue, applied to the scalp, or a control preparation. After 16 weeks, measured hair count and diameter improved more in the treatment group. However, visual assessments by the investigator and participants did not show a statistically significant difference between groups (Tak et al., 2020).

That finding concerned a topical preparation, with no follicle implantation or injection of living cells. It does not automatically validate an injectable session sold under similar terminology. The 2026 review still calls for larger trials, standardised protocols and longer observation; the findings it discusses are not a marketing authorisation for a product (Behrangi et al., 2026).

Is follicle cloning the same as the treatments being offered?

Creating a follicle that can produce a hair is a different aim from stimulating a follicle already present in the scalp. Research directions discussed in the literature include reprogrammed cells and structures grown in the laboratory, such as organoids. They involve organising several biological components; their appearance in a scientific review does not establish that a session sold by a clinic achieves that reconstruction (Gasteratos et al., 2024).

When assessing a claim about “hair cloning”, ask where the evidence comes from: experiments with cells, an animal model or research involving people. Then check whether the procedure on offer matches the one investigated, and whether the measured outcome was actually the creation of functioning follicles. A “new” hair becoming visible in an observed area does not, by itself, explain the origin of the follicle producing it or show that the same change will occur elsewhere.

A promise to provide an unlimited supply for someone with insufficient donor hair therefore needs separate examination. Evidence would need to track both the harvested sites and the treated regions over time, using a method capable of distinguishing existing follicles from those claimed to have formed anew. The trials described above do not establish that such a service can be provided to every patient, nor do they remove the need to assess the donor region when planning surgery.

This distinction also helps when an announcement predicts a date for the “end of baldness”. Ask which stages of development have actually been completed and which questions remain unresolved, without treating a research announcement as a timetable for your own care. You can continue investigating the cause of your current hair loss while following developments in the field, with time to weigh the available options before deciding whether to have any procedure.

How can you assess a useful and lasting improvement?

First ask what the proposed outcome means: more hairs counted within a small marked area, greater average shaft diameter or a visible change across the scalp. Those measurements answer different questions. A percentage with no starting value, measurement area or comparison group gives you little basis for judging what you might notice in everyday life.

Photographs should allow a fair comparison, using consistent lighting and framing. Ask whether other treatments began during follow-up and whether the results account for everyone who received the intervention. Selected photographs may illustrate individual cases, but they cannot establish your own likelihood of benefiting from the proposed procedure.

How long the improvement lasts matters alongside its initial appearance. In Tak’s trial, the 16-week observation period, small sample and recruitment at a single centre limit conclusions about longer-term outcomes (Tak et al., 2020). Before accepting a proposal, establish when results would be assessed, the conditions for any further session and the plan if the expected improvement does not appear.

Which types of hair loss are relevant to this research?

The studies discussed here mainly concern androgenetic alopecia, and their findings cannot automatically be extended to every cause of hair loss. Eligibility criteria select particular groups, sometimes including few women or excluding certain patterns of loss. An advertisement saying “men and women” or “all types of alopecia” therefore cannot establish whether the research applies to you.

An assessment should explain the likely cause of the shedding or thinning and examine the scalp before treatment is proposed. Bring information about when the problem started, the treatments you have tried and the changes you have noticed, together with your current prescriptions. The clinician can then decide whether further investigation or a different approach is needed, without assuming that a regenerative procedure addresses the cause.

Thinning hair may also raise a separate question about the suitability of surgery. Our article on a hair transplant for thinning hair discusses what needs consideration. Ask why each option is being suggested for your circumstances and what postponing it would mean, rather than selecting a procedure because it is described as the newest approach.

What happens during the procedures being studied?

There is no single sequence that covers every commercial proposal. Some research uses small samples of scalp processed into tissue fragments; other approaches use cells from fatty tissue or preparations manufactured from cellular constituents. The harvesting and preparation stages need separate explanation, without treating a mixed tissue preparation as a pure population of stem cells (Gasteratos et al., 2024).

Next, ask how the product would be delivered and why that route has been chosen. A topical application, an injection and a surgical operation are different interventions, even when the brochure describes each as “regeneration”. The information provided before treatment should identify the product, its source, the responsible professional and where preparation or treatment will take place.

Clarify the arrangements afterwards, including examinations, local care, any restrictions and a contact for concerns. A timetable from a study of a scalp lotion cannot serve as aftercare advice following a biopsy or an injection. You need instructions appropriate to the actual procedure and an opportunity to discuss them before giving consent, including any practical implications for work or travel.

How do you check the rules in the UK or France?

The regulatory position depends on the product, how it has been processed and its intended use. The European Medicines Agency explains that substantially manipulated cells, or cells used for a different essential function, can fall within the advanced therapy medicinal product framework. It would therefore be inaccurate to place every procedure containing the word “cell” into one regulatory category (EMA, n.d.).

In the UK, the MHRA oversees advanced therapy medicines, their clinical trials and marketing authorisations. Its guidance also describes specific routes for certain unlicensed products, including hospital exemption and the “specials” scheme; these do not amount to a general endorsement of a treatment for hair loss. Ask the provider to identify the applicable route and the documentation supporting it, rather than inferring approval from availability at a clinic (MHRA, 2026).

For a proposal in France, ask the relevant authority, including the ANSM where applicable, to verify its status. The EMA recommends checking when an advanced therapy is offered without clear evidence of authorisation or with excessive claims. A scientific publication and permission to supply a product answer separate questions; when travelling elsewhere, establish the rules in the country of treatment rather than assuming the UK or European framework applies (EMA, n.d.).

What risks and recovery arrangements need discussion?

Using material collected from your own body does not remove every risk from the procedure. Gasteratos and colleagues describe possible pain, bruising or scarring associated with different harvesting methods. The information you receive needs to address collection, processing and administration, including any additional substances used, rather than discussing only where the cells originated (Gasteratos et al., 2024).

Small studies are poorly placed to detect rare complications and may leave longer-term safety questions unanswered. Reports of no serious events over a few months need to be understood within that limit. The EMA also warns about unregulated advanced therapies, although this general warning does not establish an identical level of risk for every preparation offered for hair loss (EMA, n.d.).

Before any procedure, find out who can examine you if severe pain or an unexpected symptom develops, and how to obtain that assessment promptly. Following a surgical hair transplant, the NHS advises contacting the treating clinic as soon as possible in those circumstances (NHS, 2023). If several interventions are combined, establish the follow-up for each instead of assuming that having a contact number fully addresses your care needs.

Can these approaches be combined with other treatments?

Combination treatment makes results harder to interpret. If someone starts a medical treatment at the same time as a cell-based preparation, their subsequent improvement alone cannot show how much came from the additional procedure. To assess that contribution, ask for a study comparing groups receiving otherwise equivalent care, with the proposed addition as the relevant difference.

The same reasoning applies when a procedure is offered before or after transplantation. Research in thinning hair does not automatically demonstrate improved graft survival or faster growth following surgery. Ask what specific problem the addition is intended to address, how its contribution would be assessed and what would change in the treatment plan if you declined it.

Medical options already used for androgenetic alopecia should remain part of the discussion, according to your diagnosis and individual contraindications. Ask the clinician to compare their expected benefits, practical demands and monitoring with those of the proposed procedure. Do not alter a prescription in preparation for a session without advice from the professional responsible for that treatment.

How should you examine the price and conditions?

An isolated price cannot meaningfully compare procedures that share a name but use different preparations. The quotation should describe the method, planned assessments, proposed number of sessions and follow-up arrangements. Also ask what would be charged if another examination or session were suggested, without assuming that the need for repeated treatment has already been established.

Keep the medical decision separate from the financial commitment. A discount tied to immediate booking should leave you free to read the documentation and obtain another opinion. If the promised benefits are more specific than the evidence provided, resolve that discrepancy before comparing the fee with the cost of surgical transplantation.

Retain the study references, product name and written answers about the expected outcome. This lets another clinician examine the actual proposal rather than comment on an advertising label. If that information remains unavailable, you can defer your decision while still pursuing an assessment of the underlying hair loss and the options appropriate to it.

Where does surgery fit into your treatment plan?

Surgical transplantation remains a possibility for suitable patients, subject to an appropriate diagnosis, usable donor supply and realistic expectations. Our hair transplant guide explains the questions to raise during assessment. Interest in an experimental approach should leave room to discuss established options, as well as the possibility of choosing no procedure for the time being.

At Body Expert, planning a hair transplant in Istanbul starts with considering your request and explaining the proposed care. A quotation is free and without obligation, provided within 24 hours, and the postoperative follow-up included in the offer lasts 12 months. Those services relate to the proposed transplant and should not be interpreted as an offer of cell-based therapy.

Ask for each proposal to be explained with its aims and limitations before deciding. You should understand which parts involve surgery, a treatment under investigation or an idea still being researched. That distinction allows you to evaluate a new development without attributing the result you hope for to it in advance.

Sources

Behrangi, E., Amiri, S., Zeinali, R., Goodarzi, A., Roohaninasab, M., Khosravi, M., & Jafarzadeh, A. (2026). A systematic review of clinical evidence on the efficacy and safety of conditioned media, platelet-rich fibrin, stromal vascular fraction, extracellular vesicles, and stem cells in androgenetic alopecia. Stem Cell Research & Therapy, 17. Review of regenerative approaches.

European Medicines Agency. (n.d.). Advanced therapy medicinal products: Overview. Advanced therapies and warnings about unregulated products. Retrieved October 16, 2026.

Gasteratos, K., Kouzounis, K., & Goverman, J. (2024). Autologous stem cell-derived therapies for androgenetic alopecia: A systematic review of randomized control trials on efficacy, safety, and outcomes. Plastic and Reconstructive Surgery Global Open, 12(2), e5606. Review of clinical trials.

Medicines and Healthcare products Regulatory Agency. (2026, September 11). Advanced therapy medicinal products: Regulation and licensing in UK. UK regulation of advanced therapy medicines.

NHS. (2023, September 29). Hair transplant. Surgical transplantation, recovery and risks.

Tak, Y. J., Lee, S. Y., Cho, A. R., & Kim, Y. S. (2020). A randomized, double-blind, vehicle-controlled clinical study of hair regeneration using adipose-derived stem cell constituent extract in androgenetic alopecia. Stem Cells Translational Medicine, 9(8), 839–849. Randomised trial of a topically applied extract.